$2.94 Billion is the total value of Cormorant Asset Management, LP's 104 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GLUE | New | MONTE ROSA THERAPEUTICS INC | $69,550,000 | – | 3,193,973 | +100.0% | 2.36% | – |
| ARKG | New | ARK ETF TRput | $69,375,000 | – | 750,000 | +100.0% | 2.36% | – |
| ARKK | New | ARK ETF TRput | $65,390,000 | – | 500,000 | +100.0% | 2.22% | – |
| BMEA | New | BIOMEA FUSION INC | $48,434,000 | – | 3,170,872 | +100.0% | 1.64% | – |
| AMAM | New | AMBRX BIOPHARMA INCsponsored ads | $47,032,000 | – | 2,486,386 | +100.0% | 1.60% | – |
| AVTE | New | AEROVATE THERAPEUTICS INC | $44,613,000 | – | 2,030,691 | +100.0% | 1.52% | – |
| VERV | New | VERVE THERAPEUTICS INC | $40,594,000 | – | 709,224 | +100.0% | 1.38% | – |
| RAIN | New | RAIN THERAPEUTICS INC | $39,734,000 | – | 2,626,660 | +100.0% | 1.35% | – |
| CNTA | New | CENTESSA PHARMACEUTICALS PLCsponsored ads | $31,054,000 | – | 1,427,273 | +100.0% | 1.06% | – |
| ELEV | New | ELEVATION ONCOLOGY INC | $25,566,000 | – | 1,983,165 | +100.0% | 0.87% | – |
| VECT | New | VECTIVBIO HLDG AG | $25,531,000 | – | 2,226,128 | +100.0% | 0.87% | – |
| TALS | New | TALARIS THERAPEUTICS INC | $17,264,000 | – | 1,215,847 | +100.0% | 0.59% | – |
| GHRS | New | GH RESEARCH PLCordinary shares | $12,554,000 | – | 608,123 | +100.0% | 0.43% | – |
| New | CATABASIS PHARMACEUTICALS IN | $7,490,000 | – | 3,550,000 | +100.0% | 0.25% | – | |
| GRPH | New | GRAPHITE BIO INC | $5,931,000 | – | 203,153 | +100.0% | 0.20% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.